Adverum Biotechnologies Inc expected to post a loss of $1.47 a share - Earnings Preview

Adverum Biotechnologies

07/08/2024 03:05

* Adverum Biotechnologies Inc  ADVM.OQ   ADVM.O  is expected
to show a rise in quarterly revenue when it reports  results on
August 9 (estimated) for the period ending June 30 2024
    * The Redwood City California-based  company is expected to
report
revenue of $88.33 thousand, according to the mean estimate from
6 analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Adverum Biotechnologies
Inc is
for a loss of $1.47 per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Adverum
Biotechnologies Inc is $30.00​, above​ its last closing price
of $6.70. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Mar. 31 2024  -1.55       -1.40      -1.50     Missed  -6.8
 Dec. 31 2024  -3.35       -3.37      -2.30     Beat    31.7
 Sep. 30 2023  -3.06       -3.15      -3.30     Missed  -4.7​
 Jun. 30 2023  -3.12       -3.29      -3.10     Beat    5.7
 ​​Dec.        -3.20       -3.20      -2.90     Beat    9.5
 31 2022                                                
 Dec. 31 2022  -3.72       -3.62      -3.30     Beat    8.9​
 Sep. 30 2022  -3.03                  -4.00             -15.9
 Jan. 1 0001   -3.58                  -4.40             -29.4
 This summary was machine generated August 7 at 02:04 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)